Masaharu Ishihara

Masaharu Ishihara

Nishinomiya-hama, 6638131, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 251 publications

Authors' reply to "Unaddressed research gaps in antithrombotic therapy following drug-coated balloon angioplasty for peripheral artery disease".

Authors' reply to "Unaddressed research gaps in antithrombotic therapy following drug-coated balloon angioplasty for peripheral artery disease".

Journal: Heart and vessels
Published: August 07, 2026

Impact of 1-month dual antiplatelet therapy after treatment with drug-coated balloon for femoropopliteal artery disease.

Impact of 1-month dual antiplatelet therapy after treatment with drug-coated balloon for femoropopliteal artery disease.

Journal: Heart and vessels
Published: May 16, 2026

Ejection fraction-dependent prognostic value of discharge albuminuria in acute decompensated heart failure.

Ejection fraction-dependent prognostic value of discharge albuminuria in acute decompensated heart failure.

Journal: Journal of cardiology
Published: May 01, 2026

Three-year outcomes of the TCD-17187 (Kanshas) drug-coated balloon for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery.

Three-year outcomes of the TCD-17187 (Kanshas) drug-coated balloon for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery.

Journal: CVIR endovascular
Published: January 28, 2026

CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.

CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.

Journal: Cardiovascular intervention and therapeutics
Published: December 05, 2025

Autologous peripheral blood mononuclear cell-loaded injectable cell scaffold (ICS-001) for revolutionising angiogenic therapy: a study protocol for an exploratory clinical trial.

Autologous peripheral blood mononuclear cell-loaded injectable cell scaffold (ICS-001) for revolutionising angiogenic therapy: a study protocol for an exploratory clinical trial.

Journal: BMJ open
Published: October 23, 2025

How to manage patients with diabetes suffering from unstable blood glucose control due to insulin antibodies.

How to manage patients with diabetes suffering from unstable blood glucose control due to insulin antibodies.

Journal: Endocrine
Published: October 08, 2025

Impact of Anemia on Cardiovascular Outcomes in Patients with Acute Myocardial Infarction.

Impact of Anemia on Cardiovascular Outcomes in Patients with Acute Myocardial Infarction.

Journal: International heart journal
Published: October 01, 2025

Atrial Natriuretic Peptide at Discharge as a Predictive Marker for Early Rehospitalization in Patients With Heart Failure With Preserved Ejection Fraction.

Atrial Natriuretic Peptide at Discharge as a Predictive Marker for Early Rehospitalization in Patients With Heart Failure With Preserved Ejection Fraction.

Journal: Journal of the American Heart Association
Published: August 12, 2025

Heterozygous transferrin receptor 1 deletion reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

Heterozygous transferrin receptor 1 deletion reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

Journal: Atherosclerosis plus
Published: July 08, 2025

Total clinical course of left insular stroke-induced bradycardia-tachycardia and takotsubo syndrome: A case report of stroke-heart syndrome.

Total clinical course of left insular stroke-induced bradycardia-tachycardia and takotsubo syndrome: A case report of stroke-heart syndrome.

Journal: Journal of cardiology cases
Published: May 14, 2025

Rationale and Design of the ESPIAL Trial　- A Prospective, Randomized, Exploratory Study to Evaluate the Effect of Esaxerenone on Reduction of Urinary Albumin to Creatinine Ratio in Hypertensive Patients Concomitant With Heart Failure and Albuminuria.

Rationale and Design of the ESPIAL Trial　- A Prospective, Randomized, Exploratory Study to Evaluate the Effect of Esaxerenone on Reduction of Urinary Albumin to Creatinine Ratio in Hypertensive Patients Concomitant With Heart Failure and Albuminuria.

Journal: Circulation reports
Published: April 14, 2025
Showing 1-12 of 251

Last Updated: 09/26/2026